[The pleiotropic drug resistance phenotype: role of reverting agents "in vitro" and "in vivo"].
Petrini
M
M
Università di Pisa.
Carulli
G
G
Mattii
L
L
Sabbatini
A
A
Pardi
C
C
Caracciolo
F
F
Grassi
B
B
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002438:Cefoperazone / Q000494:pharmacology*; D002648:Child; D016572:Cyclosporine / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology; D004341:Drug Evaluation; D004357:Drug Synergism; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism; D009529:Nicardipine / Q000494:pharmacology* / Q000627:therapeutic use; D010641:Phenotype; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D014700:Verapamil / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D002438:Cefoperazone; D004317:Doxorubicin; D016572:Cyclosporine; D014700:Verapamil; D009529:Nicardipine
Il fenotipo della chemioresistenza pleiotropica: ruolo degli agenti revertanti "in vitro" ed "in vivo".